CA3029596A1 - Methodes pour le traitement du cancer - Google Patents

Methodes pour le traitement du cancer Download PDF

Info

Publication number
CA3029596A1
CA3029596A1 CA3029596A CA3029596A CA3029596A1 CA 3029596 A1 CA3029596 A1 CA 3029596A1 CA 3029596 A CA3029596 A CA 3029596A CA 3029596 A CA3029596 A CA 3029596A CA 3029596 A1 CA3029596 A1 CA 3029596A1
Authority
CA
Canada
Prior art keywords
foregoing
cancer
compound
derivatives
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3029596A
Other languages
English (en)
Inventor
Chiang Jia Li
Matthew HITRON
Youzhi Li
Wei Li
Waldo ORTUZAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Oncology Inc
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Publication of CA3029596A1 publication Critical patent/CA3029596A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3029596A 2016-06-28 2017-06-27 Methodes pour le traitement du cancer Abandoned CA3029596A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662355410P 2016-06-28 2016-06-28
US62/355,410 2016-06-28
US201762506929P 2017-05-16 2017-05-16
US62/506,929 2017-05-16
US201762514059P 2017-06-02 2017-06-02
US62/514,059 2017-06-02
PCT/US2017/039430 WO2018005444A2 (fr) 2016-06-28 2017-06-27 Méthodes pour le traitement du cancer

Publications (1)

Publication Number Publication Date
CA3029596A1 true CA3029596A1 (fr) 2018-01-04

Family

ID=59325662

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3029596A Abandoned CA3029596A1 (fr) 2016-06-28 2017-06-27 Methodes pour le traitement du cancer

Country Status (4)

Country Link
JP (1) JP2019519573A (fr)
CA (1) CA3029596A1 (fr)
TW (1) TW201806592A (fr)
WO (1) WO2018005444A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3765402A4 (fr) * 2018-03-16 2021-11-17 The Board of Trustees of the Leland Stanford Junior University Analyse de la réponse à des agents thérapeutiques dans le cancer
CN112955143B (zh) * 2018-09-18 2023-10-13 北京强新生物科技有限公司 非酒精性脂肪性肝病的治疗

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010537640A (ja) 2007-08-27 2010-12-09 ボストン バイオメディカル， インコーポレイテッド マイクロｒｎａ模倣剤または阻害剤としての非対称性ｒｎａ二重鎖の組成物
CN101848908B (zh) 2007-09-06 2014-07-02 北京强新生物科技有限公司 激酶抑制剂的组合物及其在治疗癌症和其它与激酶相关的疾病中的用途
EP2200431B1 (fr) 2007-09-10 2016-07-20 Boston Biomedical, Inc. Compositions et procédés nouveaux pour le traitement du cancer
WO2011116399A1 (fr) 2010-03-19 2011-09-22 Boston Biomedical, Inc. Nouveaux procédés de ciblage des cellules souches du cancer
RU2571661C2 (ru) 2010-03-19 2015-12-20 Бостон Байомедикал, Инк. Новые соединения и композиции для нацеливания на злокачественные стволовые клетки
CN103402993A (zh) 2011-03-04 2013-11-20 舟山海中洲新生药业有限公司 用于疾病治疗的4，9-二羟基-萘并[2,3-b] 呋喃新型酯
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
AU2014243869A1 (en) 2013-03-13 2015-09-24 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
MX2017013816A (es) * 2015-04-27 2018-11-12 Boston Biomedical Inc Métodos para tratar el cáncer con un inhibidor de la vía de stat3 e inhibidor de cinasas.

Also Published As

Publication number Publication date
WO2018005444A3 (fr) 2018-02-15
TW201806592A (zh) 2018-03-01
JP2019519573A (ja) 2019-07-11
WO2018005444A2 (fr) 2018-01-04

Similar Documents

Publication Publication Date Title
US20180085341A1 (en) Methods for treating cancer
CN108495628A (zh) 苯并噻吩基选择性雌激素受体下调剂
US10646464B2 (en) Methods for treating cancer
US20180250261A1 (en) Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
US20190231735A1 (en) Methods for treating cancer
JP2020515582A (ja) 腫瘍関連マクロファージの治療における使用のための葉酸コンジュゲート
TW201731500A (zh) 用於治療癌症的方法
US20180098959A1 (en) Methods for treating cancer
CA3029596A1 (fr) Methodes pour le traitement du cancer
JP7513286B2 (ja) 化学療法難治性がんの治療のための新しい併用薬方法
JP2022504760A (ja) 化学療法難治性がんの治療のための新しい併用薬方法
EA046190B1 (ru) Новое комбинированное решение для лечения рака, резистентного к химиотерапии

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200831